# Replimune Group, Inc.: overview REPL · Nasdaq · CIK 1737953 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/repl.md) · [Financials](/companies/repl/financials.md) · [Filings](/companies/repl/filings.md) · [Insiders](/companies/repl/insiders.md) Latest reported revenue: [$0](/filings/0001104659-19-008435.md) for Q3 FY2019, three months to 2018-12-31, from the 10-Q filed Feb 14, 2019 (XBRL us-gaap:Revenues, accession 0001104659-19-008435). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.68)](/filings/0001628280-25-049884.md) | [(0.79)](/filings/0001628280-26-004805.md) | not reported | [(0.95)](/filings/0001628280-26-057099.md) | [(0.90)](/filings/0001628280-25-049884.md) | [(0.77)](/filings/0001628280-26-004805.md) | not reported | [(0.72)](/filings/0001628280-26-057099.md) | | Free cash flow | $m | [(40.7) d](/filings/0001628280-25-049884.md) | [(52.5) d](/filings/0001628280-26-004805.md) | [(54.9) d](/filings/0001628280-26-045886.md) | [(79.8)](/filings/0001628280-26-057099.md) | [(82.6) d](/filings/0001628280-25-049884.md) | [(66.1) d](/filings/0001628280-26-004805.md) | [(56.2) d](/filings/0001628280-26-045886.md) | [(75.7)](/filings/0001628280-26-057099.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.26)](/filings/0001737953-23-000009.md) | [(2.99)](/filings/0001737953-24-000008.md) | [(3.24)](/filings/0001737953-25-000009.md) | [(3.07)](/filings/0001628280-26-045886.md) | [(3.38)](/filings/0001628280-26-045886.md) | | Free cash flow | $m | [(84.5)](/filings/0001737953-23-000009.md) | [(130)](/filings/0001737953-24-000008.md) | [(191)](/filings/0001737953-25-000009.md) | [(199)](/filings/0001628280-26-045886.md) | [(285)](/filings/0001628280-26-045886.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/repl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $122.3m | 11,045,336 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $99.2m | 8,958,535 | | Added +2,719,296 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $82.0m | 7,411,581 | | Added +54,665 | | [Ridgeback Capital Investments L.P.](/funds/1423994.md) | 2026-06-30 | $80.9m | 7,310,656 | | New +7,310,656 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $50.3m | 4,541,018 | | Added +2,263,742 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $49.2m | 4,440,144 | | Added +657,907 | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $48.6m | 4,389,836 | | Added +168,000 | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $44.1m | 3,983,000 | | Added +2,808,000 | | [Caption Management, LLC](/funds/1706766.md) | 2026-06-30 | $32.7m | 2,952,800 | Call | Added +2,060,200 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $32.1m | 2,896,004 | | Added +136,884 | ## Recent filings [All 644 filings](/companies/repl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-28 | 07:05 ET | [8-K](/filings/0001104659-26-119354.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-119354 | | 2026-09-16 | 16:05 ET | [8-K](/filings/0001104659-26-108243.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-108243 | | 2026-08-14 | 16:07 ET | [10-Q](/filings/0001628280-26-057099.md) | Quarterly report, period 2026-06-30 | 0001628280-26-057099 | | 2026-08-14 | 08:10 ET | [8-K](/filings/0001104659-26-096483.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-096483 | | 2026-08-11 | 17:50 ET | [SCHEDULE 13D/A](/filings/0001104659-26-094196.md) | Ownership report, active investor, amended | 0001104659-26-094196 | | 2026-08-11 | 18:37 ET | [8-K/A](/filings/0001104659-26-093512.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-093512 | | 2026-08-10 | 07:50 ET | [8-K](/filings/0001104659-26-093042.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-093042 | | 2026-08-07 | 21:27 ET | [8-K](/filings/0001104659-26-092246.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-092246 | | 2026-07-31 | 20:02 ET | [8-K](/filings/0001104659-26-088857.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-088857 | | 2026-07-30 | 08:06 ET | [8-K](/filings/0001104659-26-088481.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-088481 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001628280-26-045886.md), filed Jun 29, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1737953 - Tickers: REPL - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 07:26 ET. No prices; not investment advice.